A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer

Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer

(2012) Giancarlo Agnelli et al.   NEW ENGLAND JOURNAL OF MEDICINE

Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial

(2011) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

New Anticoagulants

(2010) John W. Eikelboom et al.   CIRCULATION

PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma

(2010) J. R. PERRY et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial

(2010) Michael Rud Lassen et al.   LANCET

Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement

(2010) Michael Rud Lassen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

(2009) Giancarlo Agnelli et al.   LANCET ONCOLOGY

Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement

(2009) Michael Rud Lassen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of the oral direct factorXa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study

(2008) et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS